These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16219656)

  • 21. Management of hypertension: evidence from the Blood Pressure Lowering Treatment Trialists' Collaboration and from major clinical trials.
    Chalmers J; Arima H
    Pol Arch Med Wewn; 2009 Jun; 119(6):373-80. PubMed ID: 19694219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ARBs and mortality in myocardial infarction.
    Opie LH
    Cardiovasc J S Afr; 2005; 16(2):84. PubMed ID: 15915273
    [No Abstract]   [Full Text] [Related]  

  • 23. Hypertension management in outpatient visits by diabetic patients.
    Aparasu RR; Aparasu A
    Res Social Adm Pharm; 2008 Sep; 4(3):284-91. PubMed ID: 18794038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LIFE and SCOPE: what guidance do they offer alongside ALLHAT and ANBP2?
    Nicholls MG
    J Hum Hypertens; 2004 May; 18(5):295-300. PubMed ID: 14739907
    [No Abstract]   [Full Text] [Related]  

  • 27. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antihypertensive therapy in diabetes mellitus: insights from ALLHAT and the Blood Pressure-Lowering Treatment Trialists' Collaboration meta-analysis.
    Varughese GI; Lip GY
    J Hum Hypertens; 2005 Nov; 19(11):851-3. PubMed ID: 16079882
    [No Abstract]   [Full Text] [Related]  

  • 29. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysis.
    McCall KL; Craddock D; Edwards K
    Pharmacotherapy; 2006 Sep; 26(9):1297-306. PubMed ID: 16945052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hypertension 2007-2008].
    Chatzikyrkou C; Menne J; Haller H
    Med Klin (Munich); 2009 Aug; 104(8):614-21. PubMed ID: 19701732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of angiotensin receptor blockers on myocardial infarction: what are we to believe?
    Ker JA; Rheeder P
    Cardiovasc J S Afr; 2005; 16(2):81-2. PubMed ID: 15915272
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
    Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
    Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
    Pierson CA; Epstein BJ; Roberts ME
    J Am Acad Nurse Pract; 2008 Nov; 20(11):529-38. PubMed ID: 19128336
    [No Abstract]   [Full Text] [Related]  

  • 40. [Hypertension therapy for type 2 diabetics].
    Bönner G
    MMW Fortschr Med; 2007 Jun; 149(23):45, 47-8. PubMed ID: 18062579
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.